DDInter1200 DDInter1676
Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succinate derivative. To this date, it is one of the preferred beta-blockers in general clinical guidelines and it is widely prescribed in the Netherlands, New Zealand, and the US. Metoprolol was developed since 1969 by US Pharmaceutical Holdings I and FDA approved in 1978.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Metoprolol {u} (Compound) resembles {v} (Compound) Oxprenolol
Metoprolol {u} (Compound) resembles {v} (Compound) Metipranolol
Metoprolol {u} (Compound) treats {v} (Disease) hypertension
Metoprolol {u} (Compound) binds {v} (Gene) SLC22A2
Metoprolol {u} (Compound) upregulates {v} (Gene) HOOK2
Metoprolol {u} (Compound) downregulates {v} (Gene) LAP3
Metoprolol {u} (Compound) causes {v} (Side Effect) Coma
Metoprolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Levothyroxine
Metoprolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glucagon
Metoprolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pasireotide
Metoprolol (Compound) resembles Oxprenolol (Compound)
Metoprolol (Compound) resembles Metipranolol (Compound)
Metoprolol (Compound) treats hypertension (Disease)
Metoprolol (Compound) binds SLC22A2 (Gene)
Metoprolol (Compound) upregulates HOOK2 (Gene)
Metoprolol (Compound) downregulates LAP3 (Gene)
Metoprolol (Compound) causes Coma (Side Effect)
Metoprolol may cause a minor interaction that can limit clinical effects when taken with Levothyroxine
Metoprolol may cause a minor interaction that can limit clinical effects when taken with Glucagon
Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide